International Journal of Contemporary Pediatrics

Bhadke LE et al. Int J Contemp Pediatr. 2023 Mar;10(3):413-416

http://www.ijpediatrics.com

pISSN 2349-3283 | eISSN 2349-3291

An unusual case of familial hypophosphatemic rickets

Leny E. Bhadke*, Suryakant Y. Ingale, Prathamesh S. Shinde


Department of Pediatrics, B. K. L. Walawalkar Medical College, Sawarde, Ratnagiri, Maharashtra, India

Received: 16 January 2023

Accepted: 14 February 2023

*Correspondence:

Dr. Leny E. Bhadke,

E-mail: lenybhadke7@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Rickets is the failure of mineralisation of osteoid and newly formed bones in a child skeleton. It is commonly associated with vitamin D deficiency; however, it can be because of a decrease in serum phosphate level leading to inadequate mineralization of cartilage and bone, consequent skeletal deformities and growth retardation. In hypophosphatemic rickets, there are both inherited and acquired forms, where X-linked hypophosphatemic rickets (XLH) is the most prevalent genetic form and caused by mutations in the phosphate-regulating endopeptidase (PHEX) gene. XLH is associated with growth retardation and bone deformities. This rare variety was diagnosed in a 2 year 4 month old child who had brought by parents with complaint of abnormal gait. In the present case, clinical and radiographic aspects of manifestation of familial hypophosphatemic rickets are discussed.

Keywords: Rickets, Hypophosphatemic rickets, PHEX gene, Bone deformities

INTRODUCTION

Rickets and osteomalacia are disorders that result from decreased mineralization of bone matrix or osteoid caused by deficiencies of calcium or phosphorus or both.1 Rickets is usually divided into hypocalcemic and hypophosphatemic rickets, based on the deficient mineral.1 In hypophosphatemic rickets, there are both inherited and acquired forms, where X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form. XHR (X-linked hypophosphatemic rickets) is a dominant inherited disorder with a prevalence of approximately one case per 20,000 live births.2,3 It is characterized by wasting of phosphate from the kidneys which lead to chronic hyperphosphaturia and hypophosphatemia, which may or may not be associated with normal or low levels of 1,25(OH)2 vitamin D3.2 This phosphorus wasting disorder affects the bone metabolism which causes rickets in pediatric patients and osteomalacia in adults.2,4

It is caused by one or more circulating factors termed as phosphatonins, which promote phosphate excretion and impair bone mineralization rather by a defect in kidneys.2 In XHR, hyperphosphaturia is caused by mutation in the PHEX gene (phosphate regulating endopeptidase on X-chromosome), which is identified on Xp22.1 and is mainly expressed in bone and teeth.2-10 The principal phosphatonin involved in pathogenesis of XLH is fibroblast growth factor 23 (FGF23) which act as phosphaturic agents, by inhibiting phosphorus reabsorption in the proximal tubules, through sodium and phosphate cotransporters inhibition.2 Affected children usually have short stature, knock knee, bowing of legs, coxa vara and poor dental development, but Harrison’s sulcus, myopathy are uncommon.11 Untreated XHR is associated with growth retardation, bone deformities and fragility fractures.2

CASE REPORT

A 2 year 4 month old male child of a non-consanguineous parents belonging to low socioeconomic status, residing at Sawarde, Taluka- Chiplun came to pediatric OPD at our hospital with complaint of abnormal gait while walking and wide gap between two legs while standing since age of 1 year. There was no h/o polyuria, dysuria, jaundice, recurrent chest infections or recurrent attacks of diarrhea and he was not on long term anticonvulsant drugs. Birth history was significant. Child was admitted in NICU ivo preterm born at 33 weeks 5 days period of gestation and low birth weight 1.55 kg. Child was immunized as per schedule till date. After birth, breastfeeding was started after one and half month and was breastfed for 6 months. Currently he is on family diet i.e. rice, vegetables, fruits, etc. Though his milestones of development were normal but his linear growth and weight were not satisfactory as compared to other children of same age. Exposure to sunlight was adequate as he used to play along with his brother in open air.

Child’s father and twin brother (1st of twin) did not have same complaint. His mother had similar complaints like short stature and bowing of both lower limbs. Mother’s height was 130 cm. Mother’s family history was significant. Similar complaint were seen in mother’s father and one of her sibling sister.

On examination, his pulse was 108/min, blood pressure was 88/50 mmHg and temperature was normal. Anthropometric measurements revealed height 75 cm, weight 10 kg. On head to toe examination, Frontal bossing was seen, occipital prominence present, both wrist joint were widened, bowing of both lower limbs seen, B/L double malleolus was present, lordosis was present, protruded abdomen was seen and mild kyphoscoliosis were present.

Biochemical blood test are as follows: alkaline phosphatase: 490.4 U/l, albumin: 4.3 g/dl, calcium: 9.52 mg/dl, phosphorous: 2.70 mg/dl, and PTH: 54.7 pg/ml.

Both the clinical features and laboratory parameters were consistent with familial hypophosphatemic rickets. So he was started with cholecalciferol 60000 IU sachet, initially one sachet divided in 9 parts and given 3 times a day for 3 days. Presently, dose was increased to one and half cholecalciferol sachet per day in three divided doses. Child was also started with syrup calcimax-p 2.5 ml two times a day and one tablet of Alfacal 0.25 mg once a day. He was advised to continue treatment and for regular follow up.

Figure 1: Family tree.
Figure 1: Family tree.
Figure 2: Frontal bossing.
Figure 2: Frontal bossing.
Figure 3: Occipital prominence.
Figure 3: Occipital prominence.
Figure 4: Low set ear.
Figure 4: Low set ear.
Figure 5: Bowing of B/L lower limb.
Figure 5: Bowing of B/L lower limb.
Figure 6: Double malleolus.
Figure 6: Double malleolus.
Figure 7: Child mother- short stature with bowing of B/L lower limbs.
Figure 7: Child mother- short stature with bowing of B/L lower limbs.
Figure 8: X-ray both knee AP view s/o: metaphyseal cupping, splaying and fraying at distal femur, distal tibia and fibula.
Figure 8: X-ray both knee AP view s/o: metaphyseal cupping, splaying and fraying at distal femur, distal tibia and fibula.
Figure 9: X-ray of both wrist-AP view s/o: metaphyseal fraying noted at distal end of radius and ulna on both sides.
Figure 9: X-ray of both wrist-AP view s/o: metaphyseal fraying noted at distal end of radius and ulna on both sides.
Figure 10: X-ray of both ankle AP view s/o: metaphyseal cupping, splaying and fraying at distal tibia and fibula.
Figure 10: X-ray of both ankle AP view s/o: metaphyseal cupping, splaying and fraying at distal tibia and fibula.

DISCUSSION

Familial hypophosphatemic or XLH rickets is one of the most common non-nutritional rickets.12 As the disease reported to be familial and X-linked dominant, female children are affected more than their male counterparts. Father (XY) transmits only to daughter and mother (XX) transmit to both son and daughter. So, the overall ratios for girls are more. In this case, as mother suffer from this disease and her father and one of sibling sister suffer from same disease, so it is an example of X linked hypophosphatemic rickets. The classical features of rickets such as rachitic rosary, Harrison’s sulcus, myopathy, etc are less common in this disease rather visible knock-knee, bowing leg, short stature, coxa vara, genu varum/valga and tooth defects are more profound.13 In this case frontal bossing, occipital protuberance, wide wrist joint, bow legs, short stature, pigeon chest, double malleolus were observed. In nutritional rickets there is low concentration of active form of vitamin D, leading impairment of absorption of both Ca++ and PO4 from intestine. When serum Ca++ level falls, it stimulates parathyroid hormone (PTH) secretion, which in turn maintains the normal serum Ca++ level by resorption of Ca++from bone, rather than conserving from intestine and kidney. So, the Ca++ level in blood may remain within limit due to secondary hyperparathyroidism. This PTH also causes phosphates diuresis effect on kidneys lowering the serum phosphate.12 Here in familial hypophosphetemic rickets, the defect lies in the proximal tubule of the kidney, since it fails to conserve the PO4, resulting in ultimate hypophosphatemia. There is absolutely no role of PTH and there is no secondary parathyroid hormone secretion.14

Standard therapeutic management of this genetic disorder includes 0.5 to 2.0 µg of 1,25-dihydroxy-cholecalciferol: calcitriol (dicatrol), in divided doses. However, oral phosphate in capsule form providing 250 mg of phosphorus per capsule, have been suggested, alternatively. Progressive healing is usually demonstrated on repeated radiological images after 2-4 weeks of treatment. In this case, it was revealed after 4 weeks. As it is a genetic disorder this has to be continued for life long. Routine monitoring of serum Ca++ and PO4 level was also advised which would probably lead him towards good prognosis.

CONCLUSION

In conclusion, it can be stated that XLH must be considered as a differential diagnosis with any form of rickets, who has positive family history, presence of bowing of legs, knock knee, coxa vara, genu varum (rather than Harrison’s sulcus, rachitic rosary or myopathy), hypophosphatemia with corresponding phosphaturia and normal serum PTH level. However, renal, hepatic or other related causes should also be excluded as differential diagnosis.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

  1. 1. Raeder H, Shaw N, Netelenbos C, Bjerknes R. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol. 2008;159(1):S101-5.
  2. 2. Juneja H, Yadav M, Pahuja I. X-Linked hypophosphatemic rickets: A case report. Int J Curr Res. 2017;9(08):56598-600.
  3. 3. Naderi AS, Reilly RF. Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol. 2010;6(11):657-65.
  4. 4. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest. 2003;112(5):642-6.
  5. 5. Rowe PS. The molecular background to hypophosphataemic rickets. Arch Dis Child. 2000;83(3):192-4.
  6. 6. Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res. 2005;58(2):329-33.
  7. 7. Bielesz B, Klaushofer K, Oberbauer R. Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone. 2004;35(6):1229-39.
  8. 8. Rowe PS. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med. 2004;15(5):264-81.
  9. 9. Beur SM, Levine MA. Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab. 2002;87(6):2467-73.
  10. 10. Saggese G, Baroncelli GI. Hypophosphataemic rickets. Horm Res. 2000;53(3):57-60.
  11. 11. Morris RC, Ives HE. Inherited disorders of the renal tubule. In: Brenner BM, eds. The Kidney. 5th ed. Philadelphia: WB Saunders Company; 1996: 1764-1827.
  12. 12. Portale AA, Halloran BP, Morris RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989;83(5):1494-9.
  13. 13. Econs MJ, Drezner MK. Bone disease resulting from inherited disorder of renal tubule transport and vitamin D metabolism. In: Coe FL, Favus MJ, eds. Disorder of Bone and Mineral Metabolism. New York: Raven Press; 1992: 935.
  14. 14. Costa T, Marie PJ, Scriver CR, Cole DE, Reade TM, Nogrady B, et al. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab. 1981;52(3):463-72.